INTRODUCTION
In 1986, the World Health Organization (WHO) compiled``Cancer Pain Relief'', a guideline for the control of cancer pain in which morphine administration plays a central role. 1) This has prompted renewed understanding of the usefulness of morphine as an analgesic, and cancer pain management has since developed rapidly worldwide. Opioid consumption has also increased. Recently, many opioid preparations in various compositions and dosage forms have been approved, and proper knowledge of them has become necessary for their appropriate use. We, therefore, established the Terminal Care Study Group, consisting of physicians, pharmacists, and nurses, in September 2001, and developed the group into the Palliative Care Team. The team has conducted educational activities concerning the use of pain remedies and analgesic adjuvants and measures to control the adverse eŠects of opioids based on the WHO method. We have surveyed the state of concomitant medications immediately before and at the beginning of opioid usage (except injections) to assess the role of the Palliative Care Team.
MATERIALS AND METHODS

History of Activities of the Palliative Care Team and Role of Pharmacists
Municipal Ikeda Hospital (our hospital) is a medium sized public hospital for acute diseases with 364 beds. Since it has no palliative care ward, terminal cancer patients are also admitted to the general ward and given terminal care. Table 1 shows the history of the Palliative Care Team. It was started in September 2001 as the Terminal Care Study Group, with the participation of physicians, pharmacists, and nurses. The members of the Study Group were approved as a Palliative Care Team by the hospital in June, 2002, when the cancer pain treatment program of the hospital (1st edition, A4 size; 2nd edition, A6 size) was prepared. Theˆrst edition was distributed only to departments and ward stations, but the second edition was distributed to all physicians, pharmacists, and nurses.
Three pharmacists were appointed as members of Table 2 ). This program was authored and edited primarily by pharmacists. The pharmacists also participated in weekly cancer conferences and ward rounds of the Palliative Care Team. At the case conferences and ward rounds, the pharmacists designed prescriptions and made proposals on the basis of the cancer pain management program. Furthermore, they provided guidance in drug management to individual patients needing palliative care and information concerning drug therapy with palliative medicine to the hospital staŠ.
Survey of Concomitant Medications Prescribed Immediately before and at the Beginning of Opioid Usage
The survey period was 3 years from Oc- , and drugs that were prescribed immediately before the beginning, and simultaneously with, theˆrst use of an opioid in each patient were investigated. The drugs of interest were non-steroidal anti-in‰ammatory drugs (NSAIDs), laxatives, and antiemetics. Prescription data were obtained from the order entry system and sorted concerning each opioid preparation. However, patients in whom opioid injections were used were excluded. Statistical analyses of the data were performed by the Chi-square and Kruskal-Wallis tests using SPSS.
RESULTS
Characteristics of Patients Using Opioids
No signiˆcant diŠerence was observed in the male-female ratio, mean age, or department among the 3 periods ( Table 2) . As for the components of opioid preparations, the percentage of morphine decreased, oxycodone serially increased, and fentanyl also increased slightly ( Table 3) .
Comparison of Concomitant Medications Prescribed Immediately before and at the Beginning of Opioid Usage
(1) Frequency of the Use of NSAIDs and Preparations Used
NSAIDs were prescribed immediate- (Fig. 1) . Of the NSAIDs used immediately before the beginning of opioid usage, loxoprofen sodium tablets accounted for about 50％ in all 3 periods. However, the NSAID most frequently prescribed simultaneously with opioids was loxoprofen sodium tablets, accounting for 47.4％, in 2002, but etodolac tablets, accounting for 45.8％, in 2004 ( Table 4) .
(2) Frequency of the Use of Laxatives and Preparations Used
Laxatives were used immediately before opioid usage in 20 40％ of the patients in all 3 periods. However, they were used simultaneously with opioids in 48. (Fig. 2) . The laxative most frequently used was magnesium oxide powder, both immediately before and after the beginning of opioid usage ( Table 4) . (Fig. 3) . The antiemetic most frequently prescribed with opioids was prochlorperazine maleate tablets ( Table 4) .
DISCUSSION
Opioids are primary drugs in cancer pain treatment according to the WHO method, and their amount of Chi-square test usage is increasing annually in Japan as well as in other advanced countries. 2) Therefore, opioids and associated remedies must be used properly. We, thus, established the Terminal Care Study Group, consisting of physicians, pharmacists, and nurses, in September 2001 and performed educational activities concerning the use of pain remedies and adjuvant analgesics based on the``WHO method'' and measures to control the adverse eŠects of opioids. As a result, the frequency of rescue prescriptions was about 10％ until 2001, but was reported to have increased to 71.4％ in 2003. 3) In this study, to assess the roles of pharmacists in the activities of the Palliative Care Team, we evaluated the drugs prescribed immediately before and at the beginning of opioid usage (other than injections) concerning NSAIDs, which are pain remedies based on the``WHO method'', and laxatives and antiemetics, which are used for the prevention of major adverse eŠects of opioids, i.e., constipation and nausea/vomiting.
By the``WHO method'', NSAIDs are used in thê rst stage of cancer pain treatment. Also, if no su‹cient eŠect is obtained even by increasing the dose of NSAIDs, opioids are used. However, the use of NSAIDs should be continued with opioids unless there is a contraindication to them. The cancer pain treatment program of our hospital has recommended the concomitant use of etodolac tablets with a highly selective COX-2 inhibitor activity even after the beginning of opioid usage. Cancer pain treatment by the``WHO method'' requires strict implementation of preventive measures against the adverse eŠects of analgesics. Concerning the relationship between the plasma opioid concentration and Pharmacological activities, constipating, emetic and analgesic eŠects generally appearˆrst with an increasing plasma opioid concentration. 4) Constipation has been reported to occur in 82％ of patients using morphine, 4) and as resistance to constipation is unlikely to develop, the concomitant administration of preventive laxatives is necessary in patients using morphine. Also, nausea has been reported to appear in 40 70％ of terminal patients, and its control is another important problem. 5, 6) Particularly, nausea is considered to occur in about a third of patients administered opioids. 6,7) From these observations, administration of antiemetics is preferable. 8) There is no special laxative for the treatment of constipation due to opioids. 9) Primarily, stimulant or osmotic laxatives are used. Magnesium oxide powder, an osmotic laxative, is used frequently as a basic prescription despite its relatively weak eŠect. 10) Thus, the cancer pain management program of our hospital recommends the concomitant use of magnesium oxide powder with opioids for the prevention of constipation. If the laxative eŠect of magnesium oxide powder is insu‹cient, the program recommends the administration of stimulant laxatives. It also recommends the administration of prochlorperazine maleate tablets for the prevention of nausea. pharmacists, and nurses. These results were in parallel with the previously reported changes in the frequency of rescue prescriptions. 3) Recently, pharmacists have become actively involved in Palliative Care Teams at many general hospitals without a hospice ward. 11 13) Maruyama, et al. reported that pharmacists' constructive advice to physicians contributes to the safe and appropriate administration of opioids to cancer patients and improvements in their QOL. 13) Kataoka, et al. also reported that activities of the Palliative Care Team led to appropriate prescriptions of rescue doses. 14) At our hospital, also, the active involvement of pharmacists in the Palliative Care Team has promoted appropriate prescriptions of NSAIDs, laxatives, and anti-emetics based on the WHO pain ladder. Thus, the active involvement of pharmacists in the Palliative Care Team is very important for improving the patients' QOL. With the approval of even more opioid preparations expected in the future, the importance of team care will increase further.
